leflunomide has been researched along with Arthritis, Juvenile Chronic in 24 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis." | 8.87 | Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011) |
| "Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision." | 5.42 | Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015) |
| "Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis." | 4.87 | Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011) |
| "In patients with polyarticular juvenile rheumatoid arthritis, methotrexate and leflunomide both resulted in high rates of clinical improvement, but the rate was slightly greater for methotrexate." | 2.71 | Leflunomide or methotrexate for juvenile rheumatoid arthritis. ( Calvo, I; Horneff, G; Jung, LK; Lahdenne, P; Mouy, R; Saurenmann, RK; Silverman, E; Simpson, K; Spiegel, L; Stewart, JA; Strand, V; Szer, IS, 2005) |
| "Juvenile idiopathic arthritis is the most frequent chronic rheumatic disease in childhood." | 2.53 | The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. ( Horneff, G; Hügle, B, 2016) |
| "Before the biologic era, treatment of juvenile idiopathic arthritis (JIA) was often highly unsatisfactory, with children forced to endure the ill effects of lifelong disease, including pain and stiffness, disability, and even increased risk of mortality." | 2.49 | Treatment of juvenile idiopathic arthritis in the biologic age. ( Cron, RQ; Stoll, ML, 2013) |
| "Many exciting developments in the treatment of juvenile idiopathic arthritis (JIA) have emerged recently, including new tools to assess the results of clinical trials (eg, the definition of remission and a radiologic scoring tool)." | 2.43 | Update on the medical treatment of juvenile idiopathic arthritis. ( Hashkes, PJ; Laxer, RM, 2006) |
| "Prognostic factors in juvenile rheumatoid arthritis (JRA) include polyarticular onset, polyarticular disease course, and rheumatoid factor positivity; in the systemic onset subtype, persistence of systemic features at 6 months after onset confers a worse prognosis." | 2.41 | Current treatment of juvenile rheumatoid arthritis. ( Ilowite, NT, 2002) |
| " Efficacy and rate of adverse events (AEs) were evaluated during a 24-month period after tocilizumab commencement." | 1.56 | Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. ( Aalto, K; Backström, M; Grönlund, MM; Kröger, L; Markula-Patjas, K; Putto-Laurila, A; Remes-Pakarinen, T; Vähäsalo, P, 2020) |
| "Juvenile idiopathic arthritis is the most common chronic rheumatic disease of childhood resulting in disability in untreated cases." | 1.51 | Leflunomide treatment in juvenile idiopathic arthritis. ( Ayaz, NA; Çakan, M; Çakmak, F; Karadağ, ŞG; Sönmez, HE; Tanatar, A, 2019) |
| "A 10-year-old girl with juvenile idiopathic arthritis in remission presented with a flare of her arthritis." | 1.48 | Juvenile idiopathic arthritis flare due to rice bodies in the knee of a 10-year-old girl. ( Barrow, M; Faller, G; Haagensen, M, 2018) |
| "Of these 22 patients, 16 had varicella and 6 had herpes zoster." | 1.43 | Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression. ( Aeschlimann, F; Baer, W; Berthet, G; Cannizzaro, E; Heininger, U; Hofer, M; Kaiser, D; Leuvenink, R; Schroeder, S; Woerner, A, 2016) |
| "Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision." | 1.42 | Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015) |
| "Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis." | 1.38 | Leflunomide in systemic onset Juvenile idiopathic arthritis. ( Dewan, V; Jahan, A; Yadav, TP, 2012) |
| "Leflunomide treatment, as employed in actual clinical practice, was well tolerated and resulted in substantial improvements in joint and functional status outcomes in children with JIA." | 1.36 | Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. ( Foeldvari, I; Wierk, A, 2010) |
| "Following repeated liver biopsy, autoimmune hepatitis was assumed and prednisolone and azathioprine were initiated." | 1.35 | [Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report]. ( Hartmann, U; Reuss-Borst, M; Schmitt, S, 2008) |
| " Five patients withdrew because of failure to maintain efficacy, 2 withdrew their consent, and 1 withdrew because of an adverse event." | 1.33 | Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. ( Duffy, C; Goldsmith, D; Hawkins, D; Howard, P; Petty, R; Schanberg, L; Silverman, E; Spiegel, L; Strand, V, 2005) |
| "Leflunomide is a pyrimidine synthesis inhibitor used in the treatment of rheumatoid arthritis." | 1.33 | Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. ( Bhargava, VO; Kovacs, SJ; Ludden, TM; Shi, J; Wang, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Broekaert, IJ | 3 |
| Klein, A | 3 |
| Windschall, D | 3 |
| Rogalski, B | 3 |
| Weller-Heinemann, F | 3 |
| Oommen, P | 3 |
| Küster, M | 3 |
| Foeldvari, I | 4 |
| Minden, K | 3 |
| Hospach, A | 3 |
| Hufnagel, M | 3 |
| Berger, T | 3 |
| Geikowski, T | 3 |
| Quietzsch, J | 3 |
| Horneff, G | 5 |
| Brunelli, JB | 1 |
| Silva, CA | 1 |
| Pasoto, SG | 1 |
| Saa, CGS | 1 |
| Kozu, KT | 1 |
| Goldenstein-Schainberg, C | 1 |
| Leon, EP | 1 |
| Vendramini, MBG | 1 |
| Fontoura, N | 1 |
| Bonfa, E | 1 |
| Aikawa, NE | 1 |
| Faller, G | 1 |
| Haagensen, M | 1 |
| Barrow, M | 1 |
| Rocha, FAC | 1 |
| Landim, JIVD | 1 |
| Nour, ML | 1 |
| Filho, VFP | 1 |
| da Rocha, LN | 1 |
| da Silva, MFC | 1 |
| Rocha, HAL | 1 |
| Ayaz, NA | 1 |
| Karadağ, ŞG | 1 |
| Çakmak, F | 1 |
| Çakan, M | 1 |
| Tanatar, A | 1 |
| Sönmez, HE | 1 |
| Grönlund, MM | 1 |
| Remes-Pakarinen, T | 1 |
| Kröger, L | 1 |
| Markula-Patjas, K | 1 |
| Backström, M | 1 |
| Putto-Laurila, A | 1 |
| Aalto, K | 1 |
| Vähäsalo, P | 1 |
| Molina, C | 1 |
| Modesto, C | 1 |
| Martín-Begué, N | 1 |
| Arnal, C | 1 |
| Stoll, ML | 1 |
| Cron, RQ | 1 |
| Alcântara, AC | 1 |
| Leite, CA | 1 |
| Leite, AC | 1 |
| Sidrim, JJ | 1 |
| Silva, FS | 1 |
| Rocha, FA | 1 |
| Bichler, J | 1 |
| Benseler, SM | 1 |
| Krumrey-Langkammerer, M | 1 |
| Haas, JP | 1 |
| Hügle, B | 2 |
| Leuvenink, R | 1 |
| Aeschlimann, F | 1 |
| Baer, W | 1 |
| Berthet, G | 1 |
| Cannizzaro, E | 1 |
| Hofer, M | 1 |
| Kaiser, D | 1 |
| Schroeder, S | 1 |
| Heininger, U | 1 |
| Woerner, A | 1 |
| Wierk, A | 1 |
| Behrens, F | 1 |
| Koehm, M | 1 |
| Burkhardt, H | 1 |
| Jahan, A | 1 |
| Dewan, V | 1 |
| Yadav, TP | 1 |
| Fantini, F | 1 |
| Gao, JS | 1 |
| Wu, H | 1 |
| Tian, J | 1 |
| Silverman, E | 2 |
| Spiegel, L | 2 |
| Hawkins, D | 1 |
| Petty, R | 1 |
| Goldsmith, D | 1 |
| Schanberg, L | 1 |
| Duffy, C | 1 |
| Howard, P | 1 |
| Strand, V | 2 |
| Mouy, R | 1 |
| Jung, LK | 1 |
| Saurenmann, RK | 1 |
| Lahdenne, P | 1 |
| Calvo, I | 1 |
| Szer, IS | 1 |
| Simpson, K | 1 |
| Stewart, JA | 1 |
| Shi, J | 1 |
| Kovacs, SJ | 1 |
| Wang, Y | 1 |
| Ludden, TM | 1 |
| Bhargava, VO | 1 |
| Passo, M | 1 |
| Hashkes, PJ | 1 |
| Laxer, RM | 1 |
| Hartmann, U | 1 |
| Schmitt, S | 1 |
| Reuss-Borst, M | 1 |
| Ilowite, NT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study[NCT00506896] | Phase 2 | 60 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry[NCT01399281] | 9,000 participants (Anticipated) | Observational | 2011-12-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for leflunomide and Arthritis, Juvenile Chronic
| Article | Year |
|---|---|
Treatment of juvenile idiopathic arthritis in the biologic age.
Topics: Abatacept; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mo | 2013 |
The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Drug Therapy, Combination; Humans; H | 2016 |
Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheuma | 2011 |
[New drugs and treatment strategies for rheumatoid arthritis].
Topics: Adalimumab; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anti | 2003 |
Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agen | 2006 |
Update on the medical treatment of juvenile idiopathic arthritis.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Juvenile; Child; Chil | 2006 |
Current treatment of juvenile rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arth | 2002 |
2 trials available for leflunomide and Arthritis, Juvenile Chronic
| Article | Year |
|---|---|
[Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate].
Topics: Adolescent; Arthritis, Juvenile; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; | 2003 |
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents; | 2005 |
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents; | 2005 |
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents; | 2005 |
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Topics: Administration, Oral; Adolescent; Alanine Transaminase; Analysis of Variance; Antirheumatic Agents; | 2005 |
15 other studies available for leflunomide and Arthritis, Juvenile Chronic
| Article | Year |
|---|---|
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di | 2023 |
Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
Topics: Adalimumab; Adolescent; Adult; Antibodies; Antibody Formation; Antirheumatic Agents; Arthritis, Juve | 2020 |
Juvenile idiopathic arthritis flare due to rice bodies in the knee of a 10-year-old girl.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, | 2018 |
Long-term breastfeeding influences disease activity in a low-income juvenile idiopathic arthritis cohort.
Topics: Abatacept; Adalimumab; Adolescent; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthriti | 2019 |
Leflunomide treatment in juvenile idiopathic arthritis.
Topics: Adolescent; Arthritis, Juvenile; Biological Products; Child; Child, Preschool; Drug Substitution; Fe | 2019 |
Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Topics: Adolescent; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis | 2020 |
Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Arthritis, Juvenile; Child; Chronic Disease; Female; Humans | 2013 |
A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Drug Therapy, Combin | 2014 |
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Chronic Disease; Cohort Studies; | 2015 |
Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression.
Topics: Acyclovir; Adolescent; Antirheumatic Agents; Antiviral Agents; Arthritis, Juvenile; Chickenpox; Chil | 2016 |
Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Child, Preschool; F | 2010 |
Leflunomide in systemic onset Juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Female; Humans; Isoxazoles; Lefl | 2012 |
Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2005 |
Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Body Weight; Child; Child, Preschool; Drug Ad | 2005 |
[Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].
Topics: Adalimumab; Adolescent; Alanine Transaminase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2008 |